Dr Lalchandani Labs Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Dr Lalchandani Labs şirketinin toplam hissedar öz sermayesi ₹96.9M ve toplam borcu ₹36.3M olup, bu da borç-öz sermaye oranını 37.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹153.7M ve ₹56.8M dir.

Anahtar bilgiler

37.5%

Borç/özkaynak oranı

₹36.30m

Borç

Faiz karşılama oranı	n/a
Nakit	₹28.21m
Eşitlik	₹96.92m
Toplam yükümlülükler	₹56.82m
Toplam varlıklar	₹153.73m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 541299 'nin kısa vadeli varlıkları ( ₹102.2M ) kısa vadeli yükümlülüklerini ( ₹52.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: 541299 şirketinin kısa vadeli varlıkları ( ₹102.2M ) uzun vadeli yükümlülüklerini ( ₹4.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 541299 'nin net borç/öz sermaye oranı ( 8.3% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 541299 şirketinin borç/öz sermaye oranı son 5 yılda 22.2% seviyesinden 37.5% seviyesine yükseldi.

Borç Kapsamı: 541299 'nin borcu işletme nakit akışı ( 78.9% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 541299 şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.

Dr Lalchandani Labs Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Chairman & MD recently bought ₹317k worth of stock

First half 2025 earnings released: EPS: ₹0.35 (vs ₹0.20 loss in 1H 2024)

Investor sentiment improves as stock rises 20%

Dr Lalchandani Labs Limited to Report Q2, 2025 Results on Oct 14, 2024

Dr Lalchandani Labs Limited to Report First Half, 2025 Results on Oct 14, 2024

Dr Lalchandani Labs Limited, Annual General Meeting, Sep 30, 2024

Full year 2024 earnings released: EPS: ₹1.43 (vs ₹3.61 loss in FY 2023)

New minor risk - Financial data availability

Dr Lalchandani Labs Limited to Report Second Half, 2024 Results on May 30, 2024

Dr Lalchandani Labs Limited Approves Appointment of Namita Anand as Company Secretary and Compliance Officer

Dr Lalchandani Labs Limited Announces the Resignation of Archana R Jha as Company Secretary and Compliance Officer

Less than half of directors are independent

Dr Lalchandani Labs Limited Announces Resignation of Monika Joshi as Company Secretary and Compliance Officer

Dr Lalchandani Labs Limited Announces Resignation of Monika Joshi as Company Secretary and Compliance Officer

First half 2024 earnings released: ₹0.20 loss per share (vs ₹2.24 loss in 1H 2023)

New major risk - Financial position

Less than half of directors are independent

Less than half of directors are independent

Dr Lalchandani Labs Limited Announces Resignation of Archana Jha from the Office of Company Secretary

Dr Lalchandani Labs Limited, Annual General Meeting, Sep 30, 2023

Dr Lalchandani Labs Limited Appoints Monika Joshi as Company Secretary and Compliance Officer, Effective August 27, 2023

Less than half of directors are independent

Less than half of directors are independent

New major risk - Revenue and earnings growth

Full year 2023 earnings released: ₹3.61 loss per share (vs ₹2.15 profit in FY 2022)

Less than half of directors are independent

Dr Lalchandani Labs Limited to Report Fiscal Year 2023 Results on May 30, 2023

Less than half of directors are independent

Less than half of directors are independent

Dr Lalchandani Labs Limited Announces Management Changes

Dr Lalchandani Labs Limited Appoints Archana Jha as Company Secretary & Compliance Officer

First half 2023 earnings released

Less than half of directors are independent

Dr Lalchandani Labs Limited to Report First Half, 2023 Results on Nov 14, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: ₹2.15 (vs ₹2.33 in FY 2021)

Dr Lalchandani Labs Limited, Annual General Meeting, Sep 30, 2022

Less than half of directors are independent

Dr Lalchandani Labs Limited Announces Resignation of CS Swati Poddar as Company Secretary and Compliance Officer

Dr Lalchandani Labs Limited Resumes in Full Capacity At the Lab in Punjabi Bagh

Investor sentiment deteriorated over the past week

Dr Lalchandani Labs Limited to Report Fiscal Year 2022 Results on May 30, 2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS ₹2.33 (vs ₹1.09 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: ₹13.00

Dr Lalchandani Labs Limited to Report First Half, 2021 Results on Nov 13, 2020

Market pulls back on stock over the past week

New 90-day high: ₹12.10

Full year earnings released - EPS ₹1.09

Dr Lalchandani Labs Limited to Report Fiscal Year 2020 Results on Jun 30, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin